WEE1 and cancer: For WEE1 inhibition, we selected adavosertib as it was shown to effectively inhibit WEE1 activity in advanced cancer patients39, and the combination of adavosertib with carboplatin has already shown encouraging results in treating carboplatin-resistant ovarian cancer40.